Glatt, Sophie
Baeten, Dominique
Baker, Terry
Griffiths, Meryn
Ionescu, Lucian
Lawson, Alastair D G
Maroof, Ash
Oliver, Ruth
Popa, Serghei
Strimenopoulou, Foteini
Vajjah, Pavan
Watling, Mark I L
Yeremenko, Nataliya
Miossec, Pierre
Shaw, Stevan
Clinical trials referenced in this document:
Documents that mention this clinical trial
Dual IL-17A and IL-17F neutralisation by bimekizumab in psoriatic arthritis: evidence from preclinical experiments and a randomised placebo-controlled clinical trial that IL-17F contributes to human chronic tissue inflammation
https://doi.org/10.1136/annrheumdis-2017-212127
Documents that mention this clinical trial
SAT0324 Certolizumab pegol provides sustained remission and minimal disease activity in patients with psoriatic arthritis over 4 years' treatment
https://doi.org/10.1136/annrheumdis-2018-eular.2637
AB0747 The effect of certolizumab pegol on radiographic progression over 4 years of treatment in patients with psoriatic arthritis
https://doi.org/10.1136/annrheumdis-2017-eular.1961
The incidence of tuberculosis in patients treated with certolizumab pegol across indications: impact of baseline skin test results, more stringent screening criteria and geographic region
https://doi.org/10.1136/rmdopen-2014-000044
Dual IL-17A and IL-17F neutralisation by bimekizumab in psoriatic arthritis: evidence from preclinical experiments and a randomised placebo-controlled clinical trial that IL-17F contributes to human chronic tissue inflammation
https://doi.org/10.1136/annrheumdis-2017-212127
Effect of certolizumab pegol over 96 weeks in patients with psoriatic arthritis with and without prior antitumour necrosis factor exposure
https://doi.org/10.1136/rmdopen-2015-000119
FRI0489 Certolizumab pegol is associated with long-term improvements in patient-reported outcomes in psoriatic arthritis: 4-year outcomes from the rapid-psa study
https://doi.org/10.1136/annrheumdis-2017-eular.1654
FRI0508 The effect of certolizumab pegol on extra-articular manifestations of psoriatic arthritis over 4 years of treatment in patients with and without prior anti-tnf exposure
https://doi.org/10.1136/annrheumdis-2017-eular.1969
Improvements in productivity at paid work and within the household, and increased participation in daily activities after 24 weeks of certolizumab pegol treatment of patients with psoriatic arthritis: results of a phase 3 double-blind randomised placebo-controlled study
https://doi.org/10.1136/annrheumdis-2014-205198
Effects of bDMARDs on quality of life in patients with psoriatic arthritis: meta-analysis
https://doi.org/10.1136/bmjopen-2021-058497
4-year results from the RAPID-PsA phase 3 randomised placebo-controlled trial of certolizumab pegol in psoriatic arthritis
https://doi.org/10.1136/rmdopen-2017-000582
FRI0333 ACHIEVEMENT OF VERY LOW DISEASE ACTIVITY AND REMISSION TREATMENT TARGETS IS ASSOCIATED WITH REDUCED RADIOGRAPHIC PROGRESSION IN PATIENTS WITH PSORIATIC ARTHRITIS TREATED WITH CERTOLIZUMAB PEGOL
https://doi.org/10.1136/annrheumdis-2020-eular.4269
AB0742 ACHIEVEMENT OF PASDAS LOW DISEASE ACTIVITY AND VERY LOW DISEASE ACTIVITY IN PATIENTS WITH PSORIATIC ARTHRITIS TREATED WITH CERTOLIZUMAB PEGOL OVER 4 YEARS AND THE OVERLAP WITH DAPSA AND MDA DISEASE ACTIVITY TARGETS
https://doi.org/10.1136/annrheumdis-2019-eular.765
Documents that mention this clinical trial
SAT0324 Certolizumab pegol provides sustained remission and minimal disease activity in patients with psoriatic arthritis over 4 years' treatment
https://doi.org/10.1136/annrheumdis-2018-eular.2637
AB0747 The effect of certolizumab pegol on radiographic progression over 4 years of treatment in patients with psoriatic arthritis
https://doi.org/10.1136/annrheumdis-2017-eular.1961
The incidence of tuberculosis in patients treated with certolizumab pegol across indications: impact of baseline skin test results, more stringent screening criteria and geographic region
https://doi.org/10.1136/rmdopen-2014-000044
Dual IL-17A and IL-17F neutralisation by bimekizumab in psoriatic arthritis: evidence from preclinical experiments and a randomised placebo-controlled clinical trial that IL-17F contributes to human chronic tissue inflammation
https://doi.org/10.1136/annrheumdis-2017-212127
Effect of certolizumab pegol over 96 weeks in patients with psoriatic arthritis with and without prior antitumour necrosis factor exposure
https://doi.org/10.1136/rmdopen-2015-000119
FRI0489 Certolizumab pegol is associated with long-term improvements in patient-reported outcomes in psoriatic arthritis: 4-year outcomes from the rapid-psa study
https://doi.org/10.1136/annrheumdis-2017-eular.1654
FRI0508 The effect of certolizumab pegol on extra-articular manifestations of psoriatic arthritis over 4 years of treatment in patients with and without prior anti-tnf exposure
https://doi.org/10.1136/annrheumdis-2017-eular.1969
Improvements in productivity at paid work and within the household, and increased participation in daily activities after 24 weeks of certolizumab pegol treatment of patients with psoriatic arthritis: results of a phase 3 double-blind randomised placebo-controlled study
https://doi.org/10.1136/annrheumdis-2014-205198
Effects of bDMARDs on quality of life in patients with psoriatic arthritis: meta-analysis
https://doi.org/10.1136/bmjopen-2021-058497
4-year results from the RAPID-PsA phase 3 randomised placebo-controlled trial of certolizumab pegol in psoriatic arthritis
https://doi.org/10.1136/rmdopen-2017-000582
FRI0333 ACHIEVEMENT OF VERY LOW DISEASE ACTIVITY AND REMISSION TREATMENT TARGETS IS ASSOCIATED WITH REDUCED RADIOGRAPHIC PROGRESSION IN PATIENTS WITH PSORIATIC ARTHRITIS TREATED WITH CERTOLIZUMAB PEGOL
https://doi.org/10.1136/annrheumdis-2020-eular.4269
AB0742 ACHIEVEMENT OF PASDAS LOW DISEASE ACTIVITY AND VERY LOW DISEASE ACTIVITY IN PATIENTS WITH PSORIATIC ARTHRITIS TREATED WITH CERTOLIZUMAB PEGOL OVER 4 YEARS AND THE OVERLAP WITH DAPSA AND MDA DISEASE ACTIVITY TARGETS
https://doi.org/10.1136/annrheumdis-2019-eular.765
Documents that mention this clinical trial
SAT0324 Certolizumab pegol provides sustained remission and minimal disease activity in patients with psoriatic arthritis over 4 years' treatment
https://doi.org/10.1136/annrheumdis-2018-eular.2637
AB0747 The effect of certolizumab pegol on radiographic progression over 4 years of treatment in patients with psoriatic arthritis
https://doi.org/10.1136/annrheumdis-2017-eular.1961
The incidence of tuberculosis in patients treated with certolizumab pegol across indications: impact of baseline skin test results, more stringent screening criteria and geographic region
https://doi.org/10.1136/rmdopen-2014-000044
Dual IL-17A and IL-17F neutralisation by bimekizumab in psoriatic arthritis: evidence from preclinical experiments and a randomised placebo-controlled clinical trial that IL-17F contributes to human chronic tissue inflammation
https://doi.org/10.1136/annrheumdis-2017-212127
Effect of certolizumab pegol over 96 weeks in patients with psoriatic arthritis with and without prior antitumour necrosis factor exposure
https://doi.org/10.1136/rmdopen-2015-000119
FRI0489 Certolizumab pegol is associated with long-term improvements in patient-reported outcomes in psoriatic arthritis: 4-year outcomes from the rapid-psa study
https://doi.org/10.1136/annrheumdis-2017-eular.1654
FRI0508 The effect of certolizumab pegol on extra-articular manifestations of psoriatic arthritis over 4 years of treatment in patients with and without prior anti-tnf exposure
https://doi.org/10.1136/annrheumdis-2017-eular.1969
Improvements in productivity at paid work and within the household, and increased participation in daily activities after 24 weeks of certolizumab pegol treatment of patients with psoriatic arthritis: results of a phase 3 double-blind randomised placebo-controlled study
https://doi.org/10.1136/annrheumdis-2014-205198
Effects of bDMARDs on quality of life in patients with psoriatic arthritis: meta-analysis
https://doi.org/10.1136/bmjopen-2021-058497
4-year results from the RAPID-PsA phase 3 randomised placebo-controlled trial of certolizumab pegol in psoriatic arthritis
https://doi.org/10.1136/rmdopen-2017-000582
FRI0333 ACHIEVEMENT OF VERY LOW DISEASE ACTIVITY AND REMISSION TREATMENT TARGETS IS ASSOCIATED WITH REDUCED RADIOGRAPHIC PROGRESSION IN PATIENTS WITH PSORIATIC ARTHRITIS TREATED WITH CERTOLIZUMAB PEGOL
https://doi.org/10.1136/annrheumdis-2020-eular.4269
AB0742 ACHIEVEMENT OF PASDAS LOW DISEASE ACTIVITY AND VERY LOW DISEASE ACTIVITY IN PATIENTS WITH PSORIATIC ARTHRITIS TREATED WITH CERTOLIZUMAB PEGOL OVER 4 YEARS AND THE OVERLAP WITH DAPSA AND MDA DISEASE ACTIVITY TARGETS
https://doi.org/10.1136/annrheumdis-2019-eular.765
Funding for this research was provided by:
UCB Pharma
This article is maintained by: Elsevier
Article Title: Dual IL-17A and IL-17F neutralisation by bimekizumab in psoriatic arthritis: evidence from preclinical experiments and a randomised placebo-controlled clinical trial that IL-17F contributes to human chronic tissue inflammation
Journal Title: Annals of the Rheumatic Diseases
CrossRef DOI link to publisher maintained version: https://doi.org/10.1136/annrheumdis-2017-212127
Content Type: article
Copyright: Copyright © 2018 © Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2018. All rights reserved. No commercial use is permitted unless otherwise expressly granted. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.